Introduction

If your clinic treats MVA patients, medical cannabis is increasingly part of the conversation - for pain, for sleep, and especially for the psychiatric fallout of a crash: anxiety, PTSD, and insomnia. The question clinics keep asking is whether cannabis can actually be paid as an accident benefit, and what makes the difference between a cannabis treatment plan that gets approved and one that dies at the Tribunal.

The answer is not buried in some cannabis-specific rule. There is no cannabis section in the SABS. Medical cannabis is simply a treatment plan, and it rises or falls on the same "reasonable and necessary" test as every other OCF-18 your clinic submits.

The cleanest proof is J.M. v Wawanesa Mutual Insurance Company, 2019 CanLII 76963 (ON LAT), where the Tribunal ordered the insurer to pay $2,975.02 for medical cannabis prescribed for accident-related psychiatric injuries. The 2024 - 2026 cases that followed show exactly where cannabis claims fail when the same framework is applied carelessly.

Here is the framework, the winning pattern, and the losing pattern.

Cannabis Is Just a Treatment Plan: Section 15 and the Three Questions

Section 15 of the SABS covers medical benefits that are "reasonable and necessary as a result of the accident." That is the entire legal basis for medical cannabis. The Tribunal's standard for every treatment plan, cannabis included, comes from 17-001146 v Aviva Insurance Canada, applied in J.M.:

1. Goals - what the treatment is meant to achieve, and whether those goals relate to accident-related injuries. 2. Method - whether cannabis, at the prescribed dose and form, is a reasonable way to meet those goals. 3. Cost - whether the amount is proportionate to the benefit.

J.M. passed all three. The goals were concrete: improve functionality and decrease psychoactivity for accident-related anxiety, PTSD, and insomnia. The method was reasonable: cannabis recommended by a psychiatrist for those specific conditions. The cost - $2,975.02 - was found "not excessive."

What this means for your clinic: Stop treating cannabis as a special, risky category. Treat it like any other OCF-18: diagnosis tied to the accident, defensible prescriber and dose, and evidence it is working. That is the whole game.

The Winning Pattern: Make the Insurer Answer the Right Question

The decisive fact in J.M. was a gap in the insurer's own assessment. The insurer's assessor concluded cannabis was "not reasonable and necessary from a musculoskeletal perspective" - but the cannabis was prescribed for the applicant's psychological injuries. No one assessed that. The Tribunal's language is worth remembering:

> "An insurer's assessment regarding the suitability of medical cannabis for the applicant's psychological injuries was not conducted."

That missing assessment was fatal to the insurer's denial. The insurer answered the wrong question, and the plan was paid.

What this means for your clinic: When a cannabis OCF-18 comes back denied, read the section 44 report against the prescription. If the report addresses physical injuries while your cannabis plan targets psychiatric ones - anxiety, PTSD, insomnia - flag the gap immediately. That is precisely the error that won J.M., and it is an error insurers repeat. If your clinic works with psychological injuries, the credibility of the underlying diagnosis matters; see our breakdown of SIMS validity testing in psychological assessments.

The Losing Pattern: The Claimant's Own Words

Effectiveness is where most cannabis claims die - and the deciding evidence is usually the claimant's own mouth.

In an April 2026 TD General Insurance decision, three cannabis claims totalling more than $11,000 were denied. At an insurer examination, the claimant said he had used cannabis for four weeks but could not point to any clear benefit. Re-examined later, he described the improvement from cannabis as roughly 10 percent - compared to 20 to 30 percent from Tylenol. The Tribunal drew on a 2024 Wawanesa decision, 2024 CanLII 94143 (ON LAT), where a cannabis claim failed after the applicant admitted the treatment was not helping.

J.M. is the mirror image. The applicant articulated specific, measurable gains: cannabis eliminated Lyrica, which "could have contributed to her dizziness and lethargy"; it improved sleep; it allowed discontinuation of other medications with negative side effects; and it reduced anxiety and suicidal ideation. Those are functional outcomes - not "I feel better."

What this means for your clinic: The Tribunal takes the claimant's own assessment of benefit seriously, in both directions. Before submitting, or before an insurer examination, make sure the patient can describe what changed and by how much. Vague answers like "it helps" are a liability. Specific answers - fewer medications, better sleep onset, lower anxiety scores - are the claim.

Pre-Existing Conditions Are Not Fatal

Insurers love the overlap argument: the patient used cannabis before, or the prescription also treats pre-existing conditions. J.M. rejected that as a complete defence:

> "Although the medical cannabis was also recommended to treat some of the applicant's pre-existing conditions, there is enough evidence to support a need for it because of her accident related injuries."

The prescription must target accident-related injuries, but it does not have to target them exclusively. Silence on the accident link, however, is fatal.

What this means for your clinic: In the OCF-18 and supporting report, name the accident-related condition the cannabis treats. Acknowledge pre-existing use or overlap if it exists - the case law shows it can survive - but do not leave the accident connection unstated.

Prescriber and Dose Must Be Defensible

A cross-jurisdiction BC decision (Civil Resolution Tribunal, July 2026) shows the ceiling. A nurse practitioner prescribed 14 grams of dried cannabis per day - far above the roughly 3 grams per day the tribunal treated as the safe upper limit - while a specialist recommended the claimant wean off. The claim failed on clinical appropriateness alone.

Ontario tribunals scrutinize the same thing: is the prescriber appropriate, and is the dose within clinical norms?

What this means for your clinic: A specialist-supported, guideline-consistent dose survives scrutiny. An outlier dose from a non-prescribing or out-of-scope clinician invites denial. If cannabis is replacing another medication - as it replaced Lyrica in J.M. - say so explicitly. The medication-sparing argument converts the claim from symptom relief into treatment optimization, and it carries weight.

Insurer Side-Arguments Fail on the Merits

In a June 2026 decision, Vice-Chair Robert Maich rejected Co-operators' challenge to a cannabis treatment plan built on the argument that the cost should belong to OHIP. He held that regulatory compliance disputes between a physician and their governing body are not an insurer's route to avoid liability - and the insurer produced no evidence the prescription was payable by OHIP anyway.

The lesson: insurers must attack the plan's clinical merit, not the prescriber's billing jurisdiction. For the broader 2026 invoicing landscape this sits inside, see legal decisions in 2026 that affect your HCAI invoicing.

The Purchase Route: Licensed Producer Only

One practical rule trips up patients and clinics alike: medical cannabis can only be purchased directly from a federally licensed producer - never from a retail cannabis store. Stores are not authorized to sell medical cannabis. Insurer adjuster guidance on cannabis explicitly directs that purchases made at a retail store be denied.

Any form counts - dried flower, topicals, extracts, edibles - as long as it is bought through a licensed producer. Prices fluctuate by product and producer, and when the criteria are met, the cost is reimbursable.

What this means for your clinic: Keep three things on file for every cannabis claim:

1. The Medical Document (or equivalent) authorizing the cannabis - including the prescriber's name and provincial registration, the daily quantity in grams, and the period of use (maximum one year). Align it with Health Canada's sample medical document. 2. Purchase receipts showing the cannabis came from a licensed producer. 3. A documented cost line tied to the prescribed daily quantity and duration.

The Clinic Checklist

  • Name the accident-related condition the cannabis treats - anxiety, PTSD, insomnia, or chronic pain.
  • Confirm the prescriber's scope and qualifications; a psychiatrist or other appropriate clinician prescribing for a diagnosed condition carries weight.
  • Keep the dose within clinical norms, and justify the form and route.
  • State the medication-sparing rationale if cannabis replaces a medication with side effects.
  • Verify the patient can describe concrete, measurable benefits - or start tracking them now.

Conclusion

Medical cannabis is not a special category under the SABS. It is a treatment plan that succeeds or fails on three questions: are the goals tied to accident-related injuries, is the method reasonable, and is the cost proportionate - with the claimant's own evidence of benefit carrying the decisive weight.

J.M. v Wawanesa is the template for everything a winning cannabis claim needs: a psychiatric diagnosis tied to the accident, a prescriber who recommended cannabis for those conditions, an insurer assessment that ignored the real basis of the prescription, and a claimant who could document concrete functional gains. The April 2026 TD General decision and the 2024 Wawanesa decision are the cautionary counterpart.

For Ontario clinics, the workflow is concrete: tie the prescription to the accident, keep the dose defensible, document measurable outcomes, keep the purchase route compliant - and force the insurer to answer the clinical question it actually faces.